Drugs / RSV LID ΔM2-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02237209 | Sep 2014 → Apr 2015 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV LID ΔM2-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02237209 ↗ |
| Known as | LIDΔM2-2 | “BACKGROUND: Live respiratory syncytial virus (RSV) candidate vaccine LIDΔM2-2 is attenuated by deletion of the RSV RNA regulatory protein M2-2, resulting in upregulated viral...” PMID 29509911 ↗ Apr 2018 |
| Modality | Vaccine | “Live respiratory syncytial virus (RSV) candidate vaccine LIDΔM2-2” PMID 29509911 ↗ Apr 2018 |
| Route | Intranasal | “single intranasal dose of 105 plaque forming units (PFU) of LIDΔM2-2” PMID 29509911 ↗ Apr 2018 |